NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...
A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...
Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...
NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...
The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease ...
Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white blood ...
Sanofi and Regeneron’s Dupixent (dupilumab) has received positive final draft guidance from the National Institute for Health ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 2026 GOLD report newly highlights disease activity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results